Fate Therapeutics FATE 深 滬
等待開盤 12-15 09:30:00 美东时间
1.15
+0.040
+3.60%
華盛通- 最 高1.165
- 今 開1.12
- 成交量 140.77万股
- 最 低 1.09
- 昨 收 1.11
- 總市值 1.32亿
- 52周最高 1.99
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6611
- 委 比 -50.03%
- 總股本 1.15亿
- 歷史最高 121.16
- 量 比 1.32
- 振 幅 6.76%
- 歷史最低 0.6611
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819 Off-The-Shelf iPSC-derived Car T-cell Program In Systemic Lupus Erythematosus And Unveiled New Preclinical Data From Next-Gen. Off-The-Shelf iPSC-Derived Car T-cell Programs For Hematologic Malignancies And Autoimmune Diseases At 2025 American Society Of Hematology Annual Meeting
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treatedFirst ex-U.S.
12-08 21:12
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York. The company’s management will engage in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET. Both presentations will be available live via webcast...
11-25 13:00
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a break...
11-18 11:55
Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of $(0.40) per share from
11-13 21:41
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported third-quarter 2025 financial results, including $225.7 million in cash, $1.7 million in revenue, and $36.5 million in operating expenses. The company highlighted progress in its FT819 CAR T-cell program for autoimmune diseases, including regulatory approvals in the UK and EU, and favorable clinical data. It also announced the first patient treated with FT836, a MICA/B-targeted CAR T-cell therapy, and Initiation of IND a...
11-13 13:30
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Needham Reiterates Hold on Fate Therapeuticsto Hold
Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.
10-27 17:40
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Fate Therapeutics announced positive data from a Phase 1 trial of FT819, an off-the-shelf CAR T-cell therapy for moderate-to-severe systemic lupus erythematosus (SLE). The trial involved 10 patients treated with FT819, showing significant reductions in disease activity and favorable safety profiles, with no dose-limiting toxicities. Patients with lupus nephritis achieved complete kidney responses, and extrarenal lupus patients experienced marked ...
10-26 15:30
Fate Therapeutics appoints new CFO to support autoimmune program expansion
Fate Therapeutics (NASDAQ:FATE) has appointed Kamal Adawi as chief financial officer, effective October 20, 2025. Adawi brings over 20 years of financial leadership experience in life sciences, includ...
10-14 20:15
